welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

key information

study id #: NCT01239758

condition: Duchenne Muscular Dystrophy

status: terminated


To evaluate the long-term safety and tolerability of ACE-031 administration in subjects with Duchenne muscular dystrophy (DMD) who participated in Study A031-03. [Note: This study was terminated based on preliminary safety data. Pending further analysis of safety data and discussion with health authorities, a new ACE-031 trial will be planned.]

ACE-031 (Extension of cohort 1 from core study, A031-03),
ACE-031 (Extension of cohort 2 from core study, A031-03),
ACE-031 (Extension of cohort 3 from core study, A031-03)

mechanism of action: Myostatin inhibitor to promote muscle growth

results: https://clinicaltrials.gov/ct2/show/results/NCT01239758

last updated: November 21, 2018